Lower Dose COVID-19 Vaccine Appears Safe, Immunogenic in Children 5 to 11 Years Old
Positive topline results were announced from a phase 2/3 trial (ClinicalTrials.gov Identifier: NCT04816643) evaluating the efficacy, safety, and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine in children 5 to 11 years of age.
Lower Dose COVID-19 Vaccine Appears Safe, Immunogenic in Children 5 to 11 Years Old (empr.com)
